Hogan & Hartson LLP

Industry:	Law Firms & Legal Services
Revenues:	$192.7 Million
Employees:	2,222

Description

Hogan & Hartson's telecommunications, media, and technology (TMT) lawyers possess an in-depth understanding of our clients' business, their increasing inter-modal competition and the regulatory environments in which they operate. With the firm's 22 offices worldwide, our TMT practice is among the most interconnected in the world. This global reach allows us to serve clients in industries that are ever more complex, increasingly reliant on cross-border transactions, and frequently subject to regulations at multiple jurisdictional levels.

Find More Jobs

Job Openings

SAP/Open Text Practice Lead Omaha , NE

SAP ISU CCS Functional Consultant Omaha , NE

Drivers Nashville , TN

Assistant San Francisco , CA

CDL-A DRIVERS Indianapolis , IN

View More Statistics

Site Statistics

Monthly Unique Visitors:	10,499
Site Rank:	147,941
Trust Rating:	Neutral
Stats by

News Archive

MTS Medication Technologies, Inc. Completes Merger with Excellere Partners. Business Wire; 12/22/2009 ...MTS and Raymond James & Associates, Inc. acted as financial advisor to MTS. Excellere Partners was advised by Hogan & Hartson LLP. About the Company Founded in 1984, MTS Medication Technologies (www.mts-mt.com) is an international provider... ...more

Leading Attorneys Band Together to Advance Corporate Ethics Dialogue Through Ethisphere-Corpedia Joint Committee on Business Ethics. Business Wire; 11/23/2009 ...Joint Committee," said Stuart Altman, Partner at Hogan & Hartson LLP. "By virtue of our membership, my fellow Committee...representatives from 10 law firms: * Stuart Altman, Partner -Hogan & Hartson LLP * Gary Anderson, Shareholder -Greenberg Traurig... ...more

Study results from Hogan & Hartson, LLP broaden understanding of oncology. Medical Letter on the CDC & FDA; 10/4/2009 According to recent research published in the American Journal of Public Health, "I examined the relationship between the Food and Drug Administration's (FDA's) use of special regulatory designations and the frequency with which labels of oncology drugs are revised to explore how the FDA's ...more